Materials and methods
chronic kidney disease, epilepsy, neurological or mental diseases, SD, visual disturbances, heart failure, End-Stage Renal Disease, diabetes
DISEASES, CARDIOVASCULAR DISEASES, EPILEPSY, SENILE DEMENTIA, MALIGNANT TUMORS, ARTERIAL HYPERTENSION, ACUTE CORONARY SYNDROME, HEART FAILURE, END-STAGE RENAL DISEASE, DISEASES, DIABETES
The research was performed from March 2021 to February 2022. 102 people with the fifth stage of chronic kidney disease, treated with renal replacement therapy by hemodialysis, were qualified for the study by a nephrologist. (Fig. Qualification scheme for the research.Ultimately, 85 patients treated with renal replacement therapy by hemodialysis (58 men, 27 women) participated in the study. In the study was recruited all patients were treated with renal replacement therapy by hemodialysis at the Clinic. The study group consisted of 39 people (29 men and 10 women), and the control group—46 people (29 men, 17 women).The study and control groups included End-Stage Renal Disease patients from Department of Nephrology, Transplantology and Internal Diseases, Pomeranian Medical University, undergoing renal replacement therapy by hemodialysis due to complete absence of diuresis. Patients in both groups received 3 hemodialysis sessions per week. The average duration of one hemodialysis session was 223,85 ± 20,47 min (X ± SD) in study group and 216,52 ± 28,92 min (X ± SD) in control group.The study group was selected based on the qualifying and disqualifying criteria for the research. The qualifying criteria for the research project were: written consent to participate in the study, complete absence of diuresis, inclusion in the program of renal replacement therapy by hemodialysis for at least 3 months (frequency three times a week), age over 18 years. The disqualifying criteria for participation in the research project were: lack of consent to participate in the study, diseases of the musculoskeletal system preventing the participation in the study, severe cardiovascular diseases (heart failure in NYHA class III or IV), acute coronary syndrome in the last three months, uncontrolled arterial hypertension, visual disturbances that cannot be corrected, poorly controlled diabetes (HbA1c levels of over 8% for 3 months), senile dementia, other neurological or mental diseases that prevent giving consent to the study or understanding the nature of the study and the conditions of participation in it; malignant tumors; surgical procedures performed in the last month; amputation of a lower limb, as a mutilation that technically precludes the possibility of conducting the examination; epilepsy.